GlobeNewswire by notified

Junshi Biosciences Announces Approval of Supplemental Application for Additional Indications of Adalimumab Injection

Share

SHANGHAI, China, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the supplemental application for additional indications of adalimumab injection (project code: UBP1211, trade name: 君邁康®) for the treatment of Crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis, plaque psoriasis in children and Crohn’s disease in children has been approved by the National Medical Products Administration (“NMPA”).

Tumor necrosis factor-α (TNF-α) is secreted by macrophages, mast cells and activated Th cells. It is a potent inducer of inflammatory response and a key regulator of innate immunity, playing a key role in the occurrence and development of various inflammatory conditions. The binding of TNF-α to TNF-α receptors can induce inflammatory responses, and it has been proven that rheumatoid arthritis, psoriasis, Crohn’s disease, ankylosing spondylitis and many other autoimmune diseases are closely related to TNF-α. Anti-TNF-α monoclonal antibodies can bind to TNF-α receptors and reduce the immune response activated by TNF-α, thereby preventing the occurrence of inflammation.

君迈康 is jointly developed by Junshi Biosciences and Mabwell (Shanghai) Bioscience Co., Ltd. In March 2022, its indications including rheumatoid arthritis, ankylosing spondylitis and psoriasis were approved by the NMPA.

“We are very pleased with the rapid commercialization of 君迈康—since its clinical use less than a year ago, it has already been approved for 8 indications and become one of the domestic adalimumab with the most indications approved in the nation,” said Dr. Ning Li, CEO of Junshi Biosciences. “We will continue collaborating with Mabwell Biosciences to provide more treatment options for a wider range of patients with autoimmune diseases, including children and adults with specific diseases, and further the Healthy China Innitiative with our dedicated efforts.”

"It was wonderful to see 君迈康 achieve 5 indication approvals all at once within a relatively short amount of time,” said Dr. Datao Liu, co-founder and CEO of Mabwell Bioscience. “To this day, many patients in China are still suffering from autoimmune diseases, which severely affect their physical functions and quality of life. The extension of 君迈康’s indications will further benefit patients in China as well as the rest of the world, providing them with treatment options that are both more effective and accessible.”

About Uveitis
Non-infectious intermediate, posterior or panuveitis (NIIPPU) is a group of immune-mediated intraocular inflammatory diseases that may cause complications such as synechia, glaucoma, cataracts, macular edema and retinopathy in patients, causing impaired vision or even blindness, and usually co-occurs with immune-mediated systemic diseases such as psoriasis and ankylosing spondylitis. According to the epidemiological research data in mainland China, its incidence rate is 152/100,000, and the incidence peaks at 24 to 44 years old.

About Crohn’s Disease
It is a chronic and relapsing inflammatory gastrointestinal disease, which is categorized as inflammatory bowel disease (IBD) together with ulcerative colitis (UC). In China, the prevalence rate of Crohn’s disease is 2.29/100,000, the average incidence rate is 1.21/100,000, and it is showing a rapid upward trend. There is currently no complete cure for Crohn’s disease. The goal of treatment is to induce and sustain remission, prevent complications, and improve quality of life.

About Crohn’s Disease in Children
According to statistics, 25% to 30% of all IBD patients in the world are children, of which Crohn’s disease accounts for the vast majority, and its incidence rate has been increasing year by year.

About Polyarticular Juvenile Idiopathic Arthritis
Juvenile idiopathic arthritis is a common rheumatic disease in childhood, with chronic joint synovitis as its main symptom. Accompanied by systemic multiple organ dysfunction, it is also an important cause of childhood disability and blindness. Polyarticular juvenile idiopathic arthritis is the most common subtype of juvenile idiopathic arthritis, accounting for about 18% to 30%.

About Plaque Psoriasis in Children
Pediatric psoriasis is an immune-mediated chronic, recurrent, inflammatory, systemic disease that occurs in children. Different populations, races, and genders are equally susceptible, and about 1/3 of patients have onset of psoriasis in childhood. The common type of psoriasis in older children is plaque psoriasis (75%), followed by guttate psoriasis (15% to 30%) and generalized pustular psoriasis (1% to 5.4%).

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.

In the face of the pandemic, Junshi Biosciences’ response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. Among the many drug candidates is JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2 and the result of the combined efforts of Junshi Biosciences, the Institute of Microbiology of the Chinese Academy of Science and Lilly. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. Meanwhile, VV116, a new oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, is in global Phase III clinical trials. The JS016 and VV116 programs are a part of the company’s continuous innovation for disease control and prevention of the global pandemic.

Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-6105 8800

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Camposol Holding PLC - Invitation to the Third Quarter 2022 Financial Results Presentation26.11.2022 00:03:54 CET | Press release

Camposol Holding PLC will announce its financial results of the third quarter of 2022 on Tuesday, November 29, at 13:00 (GMT -5). The call will be conducted by our CEO, Jose Antonio Gomez - Bazan. Use the following link to register and participate in the call: Participant Registration URL: https://register.vevent.com/register/BI64a53cb1ca2843bdb219d095254b1c94 Participants are advised to log on to the service and check their settings a few minutes before the conference call begins. About CAMPOSOL CAMPOSOL is a multinational company that provides families around the world with fresh and healthy food. We have operations in Chile, Colombia, Mexico, Peru, and Uruguay, commercial offices in North America, Europe, and Asia, a corporate office in Costa Rica, and trusted relationships with the main supermarkets worldwide, as well as customers in more than 40 countries. We are involved in the harvest, processing, and marketing of high-quality agricultural products such as avocados, blueberries,

Cool Company Ltd. - Granting of Share Options and Restricted Stock Units to Primary Insiders and Mandatory Notifications of Trade25.11.2022 22:42:08 CET | Press release

Bermuda, November 25, 2022: Reference is made to the stock exchange notice from Cool Company Ltd. (“CoolCo” or the “Company”) on November 25, 2022 announcing that the board of directors of the Company (the “Board”) had resolved to implement a long-term incentive program for employees, management and board members of the Company and its affiliates (the "LTIP"). Pursuant to the LTIP, the Board has resolved to grant options over a total number of 1,237,423 shares and 115,000 restricted stock units to employees, management and board members of the Company (equivalent to approximately 2.25% and 0.2% of the Company's share capital, respectively), of which 11,507 restricted stock units and options over a total number of 742,454 shares were granted to primary insiders of the Company (equivalent to approximately 0.02% and 1.38% of the Company's share capital, respectively). Each share option, when exercised, carries the right to acquire one share in CoolCo, giving the right to acquire up to in

Cool Company Ltd. - Approval of Long-Term Incentive Plan25.11.2022 20:13:34 CET | Press release

Bermuda, November 25, 2022: The board of directors (the “Board”) of Cool Company Ltd. (“CoolCo” or the “Company”) has resolved to implement a long-term incentive plan (the “LTIP”) for employees, management and board members of the Company and its affiliates. The overall purpose of the LTIP is to promote the success of the Company for the benefit of its shareholders, by providing a framework for the retention and incentivization of employees using the Company’s equity and thereby aligning their interests with the Company and its affiliates. The LTIP provides for the grant of equity awards, with the intention being for the initial awards to be granted as options (“Options”) and restricted stock units (the “RSUs”), as further detailed below. Shares used under the LTIP are expected to be covered by the Board's authorization to issue authorized and unissued shares in connection with a grant of warrants, options or other securities with rights to convert such securities into shares of the Co

Fingerprint Cards AB (publ) publishes the final outcome of the rights issue25.11.2022 20:10:00 CET | Press release

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS), AUSTRALIA, JAPAN, CANADA, HONG KONG, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE IN ACCORDANCE WITH APPLICABLE LAW. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE SECTION "IMPORTANT INFORMATION" AT THE END OF THE PRESS RELEASE. The final outcome in Fingerprint Cards AB’s (publ) (“Fingerprints” or the “Company”) SEK 300 million rights issue of B-units (“B-units”), consisting of new B-shares and warrants (the “Fully Guaranteed Rights Issue”) shows that 16,851,001 B-units, corresponding to approximately 84.9 per cent of the B-units offered, have been subscribed for with support of unit subscription rights. The remaining 2,987,938 B-units have been subscribed for without support of unit subscription rights, corres

Fingerprint Cards AB (publ) offentliggör slutligt utfall i företrädesemissionen25.11.2022 20:10:00 CET | Pressemelding

EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, DIREKT ELLER INDIREKT, INOM ELLER TILL USA (INKLUSIVE DESS TERRIRTORIER OCH BESITTNINGAR), AUSTRALIEN, JAPAN, KANADA, HONGKONG, NYA ZEELAND, SINGAPORE ELLER SYDAFRIKA ELLER NÅGON ANNAN JURISDIKTION DÄR DISTRIBUTION ELLER OFFENTLIGGÖRANDE SKULLE VARA OLAGLIGT ELLER KRÄVA REGISTERING ELLER ANDRA ÅTGÄRDER ENLIGT GÄLLANDE LAG. ANDRA RESTRIKTIONER ÄR TILLÄMPLIGA. VÄNLIGEN SE AVSNITTET "VIKTIG INFORMATION" I SLUTET AV DETTA PRESSMEDDELANDE. Det slutliga utfallet i Fingerprint Cards AB:s (publ) (“Fingerprints” eller “Bolaget”) företrädesemission av B-units om 300 miljoner kronor (”B-units”), bestående av nya B-aktier och teckningsoptioner (den ”Fullt Garanterade Företrädesemissionen”) visar att 16 851 001 B-units, motsvarande cirka 84,9 procent av erbjudna B-units, har tecknats med stöd av uniträtter. Återstående 2 987 938 B-units tecknades utan stöd av uniträtter, motsvarande cirka 15,1 procent av erbjudna B-units. Tillsammans utgör te